About NellOne Therapeutics, Inc.

NellOne Therapeutics, Inc. is an early stage biopharmaceutical company developing a new class of therapeutic products that will shift the paradigm of tissue healing after acute injury from scarring to complete regeneration of form and function. Multiple independent proof-of-concept studies in vitro and in animal models demonstrate the potential efficacy of the company's lead therapeutic candidates to treat skin damage due to radiation burns (e.g. after radiotherapy for cancer treatment), major trauma and cardiac tissue injury after heart attacks. The therapeutic platform is based on the activity of the NELL1 protein’s signaling pathway to restore not only tissue mass, but also the function of injured tissues.

NellOne was founded with staged funding from Battelle Ventures (Princeton, NJ) and Innovation Valley Partners (Knoxville, TN). The Company's core intellectual property is licensed from UT-Battelle, LLC, manager of Oak Ridge National Laboratory (ORNL). In 2010, the Company opened a 1,300 square foot research laboratory in Oak Ridge, Tennessee.